Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

MOLECULAR MEDICINE, published by SPRINGER, is a leading scholarly journal dedicated to advancing the fields of genetics and molecular biology with a focus on clinical applications. Since its inception in 1994, it has evolved to become a pivotal platform for disseminating innovative research findings, achieving a remarkable Q1 ranking in multiple categories, including Genetics, Molecular Biology, and Molecular Medicine as of 2023. Featuring an Open Access model since 2000, the journal ensures that cutting-edge research is freely available to the global scientific community, facilitating collaboration and knowledge exchange. With a commitment to high-quality peer-reviewed content, MOLECULAR MEDICINE serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of molecular research and its implications for medical science. For those interested in contributing to or accessing vital research in this dynamic field, MOLECULAR MEDICINE stands out as a premier choice.

Cold Spring Harbor Molecular Case Studies is a prestigious journal published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, that has garnered considerable attention in the fields of Biochemistry, Genetics, and Molecular Medicine. With a focus on the intersection of molecular biology and clinical case studies, this journal serves as a key resource for researchers and practitioners seeking to explore novel insights into genetic disorders and biomedical advances. Its impact is underscored by its categorization in Q2 in various disciplines in 2023, reflecting its significance and influence within the academic community. Although currently not labeled as Open Access, Cold Spring Harbor Molecular Case Studies provides a rigorous platform for disseminating high-quality, peer-reviewed research that drives innovation and enhances understanding in these rapidly evolving fields. As a supporter of advancing scientific knowledge, this journal is essential for those dedicated to the exploration of molecular mechanisms and their clinical implications.

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

Lung Cancer - Targets and Therapy, published by Dove Medical Press Ltd, serves as a pivotal Open Access journal dedicated to advancing knowledge and research in the field of oncology, specifically focusing on lung cancer. Since its inception in 2010, this journal has provided a platform for disseminating high-quality research articles, reviews, and clinical studies, thereby enhancing the understanding of lung cancer mechanisms, therapies, and clinical outcomes. Currently ranked in the Q2 quartile within the oncology category and positioned at rank #80 out of 404 in Scopus, it resides in the 80th percentile of its field, reflecting its significant impact and relevance. With a commitment to promoting innovative therapies and strategies, Lung Cancer - Targets and Therapy is an essential resource for researchers, healthcare professionals, and students eager to contribute to the evolving landscape of cancer treatment and research.

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

Molecular Syndromology is a premier journal focused on the intricate connections between molecular genetics and syndromology, fostering discussions that advance our understanding of genetic disorders and their clinical implications. Published by KARGER, a distinguished name in medical and scientific publishing, this journal serves as a valuable platform for researchers, clinicians, and students in the field of genetics. With its ISSN 1661-8769 and E-ISSN 1661-8777, the journal has gained recognition in its category, currently positioned in the Q4 quartile for both genetic and clinical genetics disciplines according to the latest metrics. Despite being indexed lower in Scopus rankings, it addresses crucial gaps in research and offers open access options that enhance visibility and dissemination of knowledge. As it continues to converge from 2010 to 2024, Molecular Syndromology aims to bridge the gap between molecular research and its clinical applications, making a significant impact in the evolving landscape of genetic medicine.